Last reviewed · How we verify
Golimumab treatment optimization.
Golimumab treatment optimization. is a TNF-α inhibitor (monoclonal antibody) Small molecule drug developed by Hospital de Manises. It is currently FDA-approved for Rheumatoid arthritis, Ankylosing spondylitis, Psoriatic arthritis.
Golimumab is a monoclonal antibody that blocks tumor necrosis factor-alpha (TNF-α), reducing inflammatory signaling in autoimmune and inflammatory diseases.
Golimumab is a monoclonal antibody that blocks tumor necrosis factor-alpha (TNF-α), reducing inflammatory signaling in autoimmune and inflammatory diseases. Used for Rheumatoid arthritis, Ankylosing spondylitis, Psoriatic arthritis.
At a glance
| Generic name | Golimumab treatment optimization. |
|---|---|
| Sponsor | Hospital de Manises |
| Drug class | TNF-α inhibitor (monoclonal antibody) |
| Target | TNF-α (Tumor Necrosis Factor-alpha) |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
Mechanism of action
Golimumab binds to and neutralizes TNF-α, a key pro-inflammatory cytokine that drives immune-mediated inflammation. By inhibiting TNF-α, it suppresses the inflammatory cascade responsible for tissue damage in autoimmune conditions. This mechanism allows immune tolerance to be restored and inflammatory symptoms to be controlled.
Approved indications
- Rheumatoid arthritis
- Ankylosing spondylitis
- Psoriatic arthritis
- Ulcerative colitis
- Polyarticular juvenile idiopathic arthritis
Common side effects
- Injection site reactions
- Upper respiratory tract infections
- Nasopharyngitis
- Tuberculosis reactivation
- Serious infections
- Headache
Key clinical trials
- Comparison of Two Different Golimumab Dosing Regimens for Ulcerative Colitis (PHASE4)
- Golimumab in Ulcerative Colitis (UC) Patients With Loss of Response (LOR) Followed by Dose Optimization (PHASE2)
- Optimization of Golimumab Treatment in Ulcerative Colitis (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Golimumab treatment optimization. CI brief — competitive landscape report
- Golimumab treatment optimization. updates RSS · CI watch RSS
- Hospital de Manises portfolio CI
Frequently asked questions about Golimumab treatment optimization.
What is Golimumab treatment optimization.?
How does Golimumab treatment optimization. work?
What is Golimumab treatment optimization. used for?
Who makes Golimumab treatment optimization.?
What drug class is Golimumab treatment optimization. in?
What development phase is Golimumab treatment optimization. in?
What are the side effects of Golimumab treatment optimization.?
What does Golimumab treatment optimization. target?
Related
- Drug class: All TNF-α inhibitor (monoclonal antibody) drugs
- Target: All drugs targeting TNF-α (Tumor Necrosis Factor-alpha)
- Manufacturer: Hospital de Manises — full pipeline
- Therapeutic area: All drugs in Immunology
- Indication: Drugs for Rheumatoid arthritis
- Indication: Drugs for Ankylosing spondylitis
- Indication: Drugs for Psoriatic arthritis
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing